-----BEGIN PRIVACY-ENHANCED MESSAGE----- Proc-Type: 2001,MIC-CLEAR Originator-Name: webmaster@www.sec.gov Originator-Key-Asymmetric: MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB MIC-Info: RSA-MD5,RSA, QqeuPYwTuf0PfpKfa6l05z7k4g+hC9sTU3lrec+xj8x9CSl6LAFPSH7F1dZBOSGu JWgGdU10OxbHCAVT8JJIIA== 0000932799-07-000014.txt : 20070104 0000932799-07-000014.hdr.sgml : 20070104 20070104145718 ACCESSION NUMBER: 0000932799-07-000014 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20070103 FILED AS OF DATE: 20070104 DATE AS OF CHANGE: 20070104 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: SALISBURY ROBERT C CENTRAL INDEX KEY: 0001185468 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 000-12957 FILM NUMBER: 07508749 BUSINESS ADDRESS: STREET 1: 865 S W 75TH AVENUE STREET 2: SUITE 100 CITY: PLANTATION STATE: FL ZIP: 33324 BUSINESS PHONE: 9542338746 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: ENZON PHARMACEUTICALS INC CENTRAL INDEX KEY: 0000727510 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] IRS NUMBER: 222372868 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 685 ROUTE 202/206 CITY: BRIDGEWATER STATE: NJ ZIP: 08807 BUSINESS PHONE: 908 541 8671 MAIL ADDRESS: STREET 1: 685 ROUTE 202/206 STREET 2: ATT: GENERAL COUNSEL CITY: BRIDGEWATER STATE: NJ ZIP: 08807 FORMER COMPANY: FORMER CONFORMED NAME: ENZON PHARMACEUTICALS INC DATE OF NAME CHANGE: 20021211 FORMER COMPANY: FORMER CONFORMED NAME: ENZON PHARMACEUTICAL INC DATE OF NAME CHANGE: 20021210 FORMER COMPANY: FORMER CONFORMED NAME: ENZON INC DATE OF NAME CHANGE: 19920703 4 1 salisbury4_ex.xml X0202 4 2007-01-03 0 0000727510 ENZON PHARMACEUTICALS INC ENZN 0001185468 SALISBURY ROBERT C C/O ENZON PHARMACEUTICALS 685 RTE 202/206 BRIDGEWATER NJ 08807 1 0 0 0 Stock Option (Right to Buy) 8.19 2007-01-03 4 A 0 15000 0 A 2008-01-03 2017-01-03 Common Stock 15000 15000 D Annual options granted to Independent Directors of Issuer pursuant to Issuer's 2001 Incentive Stock Plan and qualified under Rule 16b-3(d). The options will be fully vested and exercisable in one tranche one year after the date of the grant if the reporting person remains on the Board at that time. /s/ Craig A. Tooman, attorney in fact 2007-01-03 -----END PRIVACY-ENHANCED MESSAGE-----